Journal
PEDIATRIC BLOOD & CANCER
Volume 68, Issue 6, Pages -Publisher
WILEY
DOI: 10.1002/pbc.29006
Keywords
children; second‐ line treatment; severe chronic ITP
Categories
Funding
- National Natural Science Foundation of China [81970111]
- Beijing Natural Science Foundation of China [7192064]
- Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority [XTZD20180205]
- National Science and Technology Key Projects Authority [2017ZX09304029004]
Ask authors/readers for more resources
The study analyzed the effects of escalating treatment strategy in children with severe chronic immune thrombocytopenia (SCITP), showing that this approach can effectively improve the condition, with a remission rate of 36.7% and a sustained response rate of 68.2%. 30% of patients benefited and maintained sustained response from high-dose dexamethasone treatment. Combined treatment with eltrombopag can reduce the relapse rate of low-dose rituximab.
Objective To analyze the effects of escalating treatment strategy in children with severe chronic immune thrombocytopenia (SCITP). Methods This was a single-center, retrospective cohort study. Data from children with SCITP who received escalating treatment strategy in our center were collected between June 2017 and August 2019. The escalating strategy included three steps: Step I (six courses of high-dose dexamethasone [HDD]), Step II (HDD combined with low-dose rituximab), and Step III (eltrombopag). Results A total of 30 cases (18 males and 12 females) were included, with duration of immune thrombocytopenia (ITP) of 20.5 (12.0-96.0) months. After treatment, the remission rate was 36.7% (11/30) and the sustained response (SR) rate was 68.2% (15/22). The distribution (remission rates) from Step I to III was as follows: nine of 30 (33.3%, 3/9); four of 30 (50%, 2/4); 17/30 (29.4%, 5/17), respectively. In eltrombopag (Step III) cases, 47.5% (8/17) maintained a platelet count of >= 50 x 10(9)/L, 37.5% (3/8) had dose tapering, and 25% (2/8) have successfully discontinued the medication. The number of patients at 12, 24, and 36 months were 30, seven, and two, with a total response and remission rates of 80% (36.7%), 57.1% (28.6%), and 50% (50%), respectively. The total relapse rate was 26.7% (8/30), and three cases from Step II and five cases from Step III. Conclusion The escalating strategy for children SCITP showed an effective improvement rate with 36.7% remission and 68.2% SR, and 30% could benefit and retain SR from HDD treatment. Combined treatment with eltrombopag can reduce the relapse rate of low-dose rituximab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available